Supramolecular biomedical polymers
AssigneeSupraPolix B.V.
InventorsTristan Mes, Anton Willem Bosman, Joris Wilhelmus Peeters, Henricus Marie Janssen
Life of this patent
Estimating the term…
Abstract
The present invention relates to supramolecular biomedical polymers comprising quadruple hydrogen bonding units and to a process for preparing such a supramolecular biomedical polymer and porous biomedical implants thereof. The supramolecular biomedical polymers are particularly suitable for the production of porous biomedical implants that need high strength, elasticity, durability, and slow biodegradation, e.g. medical implants for living tissue regeneration within a mammal, such as the treatment of cardio-vascular diseases, medical prolapses, and hernias.
Claims21
A method of forming cardio-vascular tissue, comprising using a porous biomedical implant to replace a part of an artery or vein, or part or all of a venous, pulmonary, mitral, tricuspid, or aortic heart valve in a mammalian subject,
- wherein the porous biomedical implant comprises a supramolecular biomedical polymer,
- wherein the supramolecular biomedical polymer has an ultimate tensile strength of at least 35 MPa, a Young's modulus of between 40 and 160 MPa, and an elongation at break of at least 350%, as determined by test method ASTM D 1708-96 with a crosshead speed of 20 mm/min, obtainable by the process comprising reacting a compound F′ according to Formula (1):
- with:
- a diisocyanate compound C′ according to the Formula O═C═N—R3—N═C—O;
- a functionalized polymer A′ according to the Formula P-(FG1)w;
- and
- a compound B′ according to the Formula FG2-R4-FG3;
- wherein:
- X is O or S;
- k is an integer of 1 to 20;
- n is an integer of 0 to 8;
- R1 is a C1-C13 alkyl group;
- R2 is a functional group selected from OH, SH and NH2;
- P is a polymer, with the proviso that it is neither poly(ethyleneglycol) nor polycaprolactone;
- FG1, FG2 and FG3 are functional groups independently selected from OH and NH2;
- w is in the range of about 1.8 to about 2;
- functionalized polymer A′ has a number average molecular weight Mn, as determined from its hydroxyl value, of about 1000 to about 2000 Da, and is selected from hydroxy terminated poly(1,6-hexanediol) carbonate, poly(tetramethylene glycol), and FG1-functionalized hydrogenated polybutadiene;
- R3 is a linear C4-C20 alkylene group;
- R4 is a linear C2-C20 alkylene group;
- wherein the molar ratio of compounds A′, B′, C′ and F′ expressed as A′:B′:C′:F′ is between 1:1.5:3.5:1 and 1:2:4:1;
- and
- wherein the porous biomedical implant acts as a scaffold for the formation of new cardio-vascular tissue.
A method of treating a medical condition requiring reconstruction surgery, support or augmentation, the treatment comprising surgically implanting a porous biomedical implant at a site of a mammalian subject that needs reconstruction surgery, support or augmentation, wherein the porous biomedical implant acts as a scaffold for the formation of new tissue, wherein the porous biomedical implant comprises a supramolecular biomedical polymer, wherein the supramolecular biomedical polymer has an ultimate tensile strength of at least 35 MPa, a Young's modulus of between 40 and 160 MPa, and an elongation at break of at least 350%, as determined by test method ASTM D 1708-96 with a crosshead speed of 20 mm/min, obtainable by the process comprising reacting a compound F′ according to Formula (1):
- with:
- a diisocyanate compound C′ according to the Formula O═C═N—R3—N═C═O;
- a functionalized polymer A′ according to the Formula P-(FG1)w;
- and
- a compound B′ according to the Formula FG2-R4-FG3;
- wherein:
- X is O or S;
- k is an integer of 1 to 20;
- n is an integer of 0 to 8;
- R1 is a C1-C13 alkyl group;
- R2 is a functional group selected from OH, SH and NH2;
- P is a polymer, with the proviso that it is neither poly(ethyleneglycol) nor polycaprolactone;
- FG1, FG2 and FG3 are functional groups independently selected from OH and NH2;
- w is in the range of about 1.8 to about 2;
- functionalized polymer A′ has a number average molecular weight Mn, as determined from its hydroxyl value, of about 1000 to about 2000 Da, and is selected from hydroxy terminated poly(1,6-hexanediol) carbonate, poly(tetramethylene glycol), and FG1-functionalized hydrogenated polybutadiene;
- R3 is a linear C4-C20 alkylene group;
- R4 is a linear C2-C20 alkylene group;
- wherein the molar ratio of compounds A′, B′, C′ and F′ expressed as A′:B′:C′:F′ is between 1:1.5:3.5:1 and 1:2:4:1;
- and
- wherein the medical condition is chosen from prolapse, pelvic organ prolapse, compartment syndrome, constrictive pericarditis, hemopneumothorax, hemothorax, injuries to the Dura mater, abdominal hernias, diaphragmatic hernias, hiatal hernias, pelvic hernias, anal hernias, intracranial hernias, spigelian hernias, hernias of the nucleus pulposus of the intervertebral discs, and stress urinary incontinence.
Dependencies are inferred from the claim text.